USD 7.03
(2.18%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 76.84 Million USD | -26.92% |
2022 | 105.16 Million USD | 8.1% |
2021 | 97.28 Million USD | 87.42% |
2020 | 51.9 Million USD | 53.3% |
2019 | 33.85 Million USD | -90.17% |
2018 | 344.32 Million USD | -38.6% |
2017 | 560.79 Million USD | 79.4% |
2016 | 312.6 Million USD | 40.85% |
2015 | 221.93 Million USD | 24.53% |
2014 | 178.22 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 66.57 Million USD | -13.37% |
2024 Q2 | 65.18 Million USD | -2.08% |
2023 Q1 | 95.85 Million USD | -8.85% |
2023 Q2 | 69.74 Million USD | -27.24% |
2023 FY | 76.84 Million USD | -26.92% |
2023 Q4 | 76.84 Million USD | 16.58% |
2023 Q3 | 65.91 Million USD | -5.49% |
2022 Q2 | 113.49 Million USD | -6.12% |
2022 Q1 | 120.9 Million USD | 24.28% |
2022 Q4 | 105.16 Million USD | -2.76% |
2022 Q3 | 108.14 Million USD | -4.71% |
2022 FY | 105.16 Million USD | 8.1% |
2021 Q1 | - USD | -100.0% |
2021 Q2 | 72.72 Million USD | 0.0% |
2021 Q3 | 89.05 Million USD | 22.46% |
2021 Q4 | 97.28 Million USD | 9.24% |
2021 FY | 97.28 Million USD | 87.42% |
2020 Q4 | 51.9 Million USD | 0.0% |
2020 FY | 51.9 Million USD | 53.3% |
2020 Q1 | - USD | 0.0% |
2019 Q2 | 447.26 Million USD | -3.1% |
2019 FY | 33.85 Million USD | -90.17% |
2019 Q3 | 436.24 Million USD | -2.46% |
2019 Q1 | 461.57 Million USD | 34.05% |
2018 Q2 | 487.44 Million USD | -3.64% |
2018 Q3 | 409.92 Million USD | -15.9% |
2018 Q4 | 344.32 Million USD | -16.0% |
2018 FY | 344.32 Million USD | -38.6% |
2018 Q1 | 505.85 Million USD | -9.8% |
2017 Q3 | 674.44 Million USD | -4.71% |
2017 Q2 | 707.78 Million USD | 55.29% |
2017 Q1 | 455.77 Million USD | 45.8% |
2017 FY | 560.79 Million USD | 79.4% |
2017 Q4 | 560.79 Million USD | -16.85% |
2016 FY | 312.6 Million USD | 40.85% |
2016 Q4 | 312.6 Million USD | 0.35% |
2016 Q3 | 311.5 Million USD | 1.59% |
2016 Q2 | 306.62 Million USD | 55.8% |
2016 Q1 | 196.8 Million USD | -11.32% |
2015 Q3 | 247.2 Million USD | 63.23% |
2015 Q2 | 151.44 Million USD | -8.55% |
2015 Q4 | 221.93 Million USD | -10.22% |
2015 FY | 221.93 Million USD | 24.53% |
2015 Q1 | 165.61 Million USD | -7.08% |
2014 Q4 | 178.22 Million USD | 0.0% |
2014 FY | 178.22 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ANI Pharmaceuticals, Inc. | 904.42 Million USD | 91.503% |
Aquestive Therapeutics, Inc. | 57.41 Million USD | -33.841% |
Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 93.278% |
Cosmos Health Inc. | 66.29 Million USD | -15.919% |
Cyclo Therapeutics, Inc. | 13.24 Million USD | -480.1% |
Esperion Therapeutics, Inc. | 205.79 Million USD | 62.658% |
Cronos Group Inc. | 1.13 Billion USD | 93.225% |
Incannex Healthcare Limited | 17.04 Million USD | -350.807% |
Kala Pharmaceuticals, Inc. | 55.94 Million USD | -37.355% |
Lifecore Biomedical, Inc. | 273.7 Million USD | 71.922% |
Regencell Bioscience Holdings Limited | 8.43 Million USD | -810.726% |
Sunshine Biopharma, Inc. | 27.34 Million USD | -181.015% |
Sunshine Biopharma, Inc. | 27.34 Million USD | -181.015% |
SCYNEXIS, Inc. | 128.41 Million USD | 40.154% |
Safety Shot Inc | 12.7 Million USD | -504.673% |
Theratechnologies Inc. | 77.76 Million USD | 1.183% |
Alpha Teknova, Inc. | 128.58 Million USD | 40.236% |
Universe Pharmaceuticals INC | 53.28 Million USD | -44.217% |
Pacira BioSciences, Inc. | 1.57 Billion USD | 95.119% |
Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -416.008% |
Dynavax Technologies Corporation | 997.09 Million USD | 92.293% |
Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 83.686% |
Radius Health, Inc. | 1.71 Billion USD | 95.521% |
China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -232.29% |
Alvotech | 950.09 Million USD | 91.911% |
Intra-Cellular Therapies, Inc. | 728.29 Million USD | 89.448% |
SIGA Technologies, Inc. | 254.83 Million USD | 69.844% |
Shineco, Inc. | 84.17 Million USD | 8.708% |
Silver Spike Investment Corp. | 88.57 Million USD | 13.24% |
Petros Pharmaceuticals, Inc. | 33.79 Million USD | -127.392% |
Embecta Corp. | 1.21 Billion USD | 93.672% |
Harrow Health, Inc. | 311.75 Million USD | 75.35% |
Procaps Group, S.A. | 460.18 Million USD | 83.3% |
Biofrontera Inc. | 27.93 Million USD | -175.129% |
DURECT Corporation | 45.18 Million USD | -70.061% |
PainReform Ltd. | 9.93 Million USD | -673.907% |
Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 94.546% |
OptiNose, Inc. | 107.72 Million USD | 28.665% |
RedHill Biopharma Ltd. | 23.04 Million USD | -233.443% |
Organogenesis Holdings Inc. | 460.02 Million USD | 83.295% |
Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 6.025% |
ProPhase Labs, Inc. | 91.92 Million USD | 16.402% |
Phibro Animal Health Corporation | 982.18 Million USD | 92.176% |
Procaps Group S.A. | 460.18 Million USD | 83.3% |
TherapeuticsMD, Inc. | 43.3 Million USD | -77.443% |
Viatris Inc. | 47.68 Billion USD | 99.839% |
Rockwell Medical, Inc. | 52.17 Million USD | -47.296% |
Aytu BioPharma, Inc. | 118.09 Million USD | 34.926% |
Tilray Brands, Inc. | 4.33 Billion USD | 98.227% |
PetIQ, Inc. | 868.22 Million USD | 91.149% |
Talphera, Inc. | 20.39 Million USD | -276.803% |
Neurocrine Biosciences, Inc. | 3.25 Billion USD | 97.636% |
Alimera Sciences, Inc. | 153.52 Million USD | 49.943% |
Assertio Holdings, Inc. | 286.41 Million USD | 73.169% |
Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -1191.203% |
Avadel Pharmaceuticals plc | 261.12 Million USD | 70.57% |
Hempacco Co., Inc. | 18.04 Million USD | -325.92% |
Alvotech | 950.09 Million USD | 91.911% |
Lantheus Holdings, Inc. | 1.65 Billion USD | 95.346% |
Kamada Ltd. | 351.96 Million USD | 78.166% |
Currenc Group, Inc. | 141.49 Million USD | 45.686% |
Indivior PLC | 1.95 Billion USD | 96.062% |
Evoke Pharma, Inc. | 7.06 Million USD | -987.197% |
Flora Growth Corp. | 23.62 Million USD | -225.273% |
Cyclo Therapeutics, Inc. | 13.24 Million USD | -480.1% |
Evolus, Inc. | 188.99 Million USD | 59.339% |
HUTCHMED (China) Limited | 1.27 Billion USD | 93.995% |
Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 94.92% |
Akanda Corp. | 8.83 Million USD | -769.333% |